Mandate

Vinge advises Nuevolution in connection with a directed share issue

May 25, 2018

The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevolution will raise proceeds of approximately SEK 110 million, before issue costs.

The share issue is directed to a number of selected Swedish and international investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ) and Redeye AB.

Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company’s shares are admitted to trading on Nasdaq First North Premier.

Vinge’s team has consisted of Dain Hård Nevonen, David Andersson, Malte Hedlund and Stephanie Stiernstedt.

Related

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026

Vinge advises Zengun in connection with its issuance of bonds in an amount of SEK 750 million and its early redemption of outstanding bonds

Vinge has advised Zengun Group AB (publ) in connection with its issuance of senior secured bonds in an amount of SEK 750 million (within a framework of SEK 1,500 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
February 20, 2026

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026